The first triple therapy inhaler for COPD containing a LAMA, LABA and inhaled steroid has been recommended for PBS listing. At its December 2017 meeting the Pharmaceutical Benefits Advisory Committee recommended an Authority Required (Streamlined) listing for GSK’s Trelegy Ellipta inhaler, which contains umeclidinium and vilanterol with fluticasone. The dry powder inhaler is indicated as ...
Already a member?
Enter your email to keep reading.